On August 12, 2024, Schaeffer Orlov S Nicole, Chief People Strategy Officer, sold 9,469 shares of Insmed Inc (NASDAQ:INSM) at a price of $72.49 per share. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 100,100 shares of the company.
Insmed Inc is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s portfolio includes treatments for conditions such as nontuberculous mycobacterial (NTM) lung disease and other bacterial infections.
Over the past year, Schaeffer Orlov S Nicole has sold a total of 125,890 shares and purchased no shares. This latest transaction continues a trend seen over the past year at Insmed Inc., where there were 36 insider sales and no insider purchases.
Insmed Inc. shares were trading at $72.49 on the day of the transaction, giving the company a market capitalization of around $12.87 billion. According to GF Value, the stock’s intrinsic value is estimated at $28.14, suggesting that the stock is significantly overvalued with a Price to GF Value ratio of 2.58.
The GF value is calculated based on historical multiples such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow and adjusted by a GuruFocus factor based on past company performance and estimates of future business results provided by Morningstar analysts.
This insider sale may be of interest to investors who track insider behavior and evaluate Insmed Inc.’s valuation metrics.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
